There is no cure for laryngeal papillomas. Conventional and experimental treatments can, at best, control the disease but many patients suffer frequent recurrences. We are currently testing photodynamic therapy (PDT), using dihematoporphyrin ether (DHE) (photofrin). The recurrence rate was reduced, and some patients are now free of disease. However, most patients still have recurrent disease, and not all responded. This project is a continued study of PDT efficacy, but with a new drug, meso- Tetra(hydroxyphenyl) Chlorin (mTHPC), which has potential for improved efficacy and lower photosensitivity. Patients with moderate to severe disease will be evaluated at fixed intervals for 6 months prior to PDT and 12 months post PDT, such that each patient will be used as his own control. The PDT group will also be compared to a concurrent control group with comparable disease severity receiving standard treatment. In addition to evaluating efficacy, we will ask why some patients respond while others do not. We will determine whether mTHPC levels in tissues correlate with response. We also will determine whether PDT with mTHPC induces changes in viral persistence or expression in clinically normal tissue. These studies should increase our understanding of PDT effectiveness.
The specific aims address the following questions: l. Does mTHPC reduce the score reflecting recurrent growth of papilloma significantly? 2. Do age at disease onset or initiation of treatment, gender or disease severity correlate with change in score from pre- to post-treatment? 3. Do tissue and plasma levels of mTHPC at the time of treatment correlate with clinical outcome? 4. Does PDT with mTHPC eliminate persistence of HPV DNA? 5. If HPV infection remains, does PDT reduce or eliminate viral transcription and does this correlate with clinical outcome?

Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1996
Total Cost
Indirect Cost
Chow, Louise T; Broker, Thomas R; Steinberg, Bettie M (2010) The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 118:422-49
Wu, Rong; Abramson, Allan L; Symons, Marc H et al. (2010) Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression. Int J Cancer 127:2230-7
Wu, Rong; Coniglio, Salvatore J; Chan, Amanda et al. (2007) Up-regulation of Rac1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas. Mol Med 13:143-50
Ralph Jr, Walter M; Liu, Kai; Auborn, Karen J (2006) CCAAT/enhancer-binding protein beta represses human papillomavirus 11 upstream regulatory region expression through a promoter-proximal YY1-binding site. J Gen Virol 87:51-9
Dackour, Raduwan; Carter, Timothy; Steinberg, Bettie M (2005) Phosphatidylinositol 3-kinase regulates early differentiation in human laryngeal keratinocytes. In Vitro Cell Dev Biol Anim 41:111-7
Shikowitz, Mark J; Abramson, Allan L; Steinberg, Bettie M et al. (2005) Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 131:99-105
Vambutas, A; DeVoti, J; Nouri, M et al. (2005) Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 23:5271-80
Abramson, Allan L; Nouri, May; Mullooly, Virginia et al. (2004) Latent Human Papillomavirus infection is comparable in the larynx and trachea. J Med Virol 72:473-7
Vambutas, Andrea; Bonagura, Vincent R; Reed, Elaine F et al. (2004) Polymorphism of transporter associated with antigen presentation 1 as a potential determinant for severity of disease in recurrent respiratory papillomatosis caused by human papillomavirus types 6 and 11. J Infect Dis 189:871-9
Bonagura, Vincent R; Vambutas, Andrea; DeVoti, James A et al. (2004) HLA alleles, IFN-gamma responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis. Hum Immunol 65:773-82

Showing the most recent 10 out of 33 publications